Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2018-02-13 Major Shareholding Noti…
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2018-02-13 English
13G/A
Major Shareholding Notification
2018-02-13 English
Regulatory Filings 2018
Regulatory Filings
2018-02-01 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions "Results of Operations and Financial Condition" and "Regulation FD Disclosure" but does not contain detailed financial statements or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It includes a press release as an exhibit, which is furnished but not filed, indicating this is an announcement rather than a full report. The document length is 3288 characters, which is relatively short and consistent with a regulatory announcement. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2018-01-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Loan and Security Agreement with Silicon Valley Bank, including details about loan tranches, interest rates, covenants, and warrants issued. It also includes references to exhibits containing the full agreements. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a call transcript, earnings release, or management report. It is primarily an announcement of a financing event and related agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8960 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2017-12-18 English
FORM 4
Director's Dealing
2017-11-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.